{"id":"W2758550989","doi":"10.1200/jco.2017.35.15_suppl.8028","title":"Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Clinical endpoint; Discontinuation; Multiple myeloma; Dexamethasone; Gastroenterology; Oncology; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002333399,0.001519691,0.001682805,0.0004296178,0.0003522661,0.001145364,0.001009405,0.001639576,0.004293005],"category_scores_gemma":[0.001174769,0.0005042242,0.002506683,0.0003341633,0.0006686351,0.001014712,0.0004416609,0.003640907,0.0008607953],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001001166,"about_ca_system_score_gemma":0.0007155859,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007409736,"about_ca_topic_score_gemma":0.002243208,"domain_scores_codex":[0.9995586,0.000246795,0.00001665378,0.00006172223,0.00003877892,0.00007739244],"domain_scores_gemma":[0.99938,0.0001420882,0.0001785928,0.0000590186,0.00003438613,0.0002058638],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9287694,0.01606419,0.003669176,0.0006214355,0.002154906,0.0001255406,0.0001773917,0.001166824,0.008208262,0.0001602864,0.002344481,0.03653817],"study_design_scores_gemma":[0.7273673,0.2519904,0.01288388,0.00007674737,0.001513699,0.0002343809,0.0000684578,0.0009594113,0.001653791,0.0003411292,0.002870706,0.00004000723],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874792,0.004886833,0.0006232476,0.0007986114,0.0002662443,0.001827536,0.002168645,0.0001409677,0.001808695],"genre_scores_gemma":[0.985782,0.002207828,0.001202952,0.001697178,0.0003206853,0.001956721,0.002802785,0.00003636366,0.003993466],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004293005,"threshold_uncertainty_score":0.0143615,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2201404032116821,"score_gpt":0.5047877075079944,"score_spread":0.2846473042963123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}